Getein Biotech (SHSE:603387) Construction In Progress: ¥277 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603387 Getein Biotech Inc SHSE:603387
77 GF Score
Price ¥8.90
GF Value ¥7.56
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Getein Biotech Construction In Progress?

Getein Biotech SHSE:603387 77 Construction In Progress is ¥277 Mil as of Mar. 2026. GuruFocus rates SHSE:603387 with a GF Score™ of 77/100 and a GF Value™ of ¥7.56 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Getein Biotech's quarterly construction in progress increased from Sep. 2025 (¥271 Mil) to Dec. 2025 (¥273 Mil) and increased from Dec. 2025 (¥273 Mil) to Mar. 2026 (¥277 Mil).

Getein Biotech's annual construction in progress increased from Dec. 2023 (¥206 Mil) to Dec. 2024 (¥225 Mil) and increased from Dec. 2024 (¥225 Mil) to Dec. 2025 (¥273 Mil).

Getein Biotech Construction In Progress Historical Data

* Premium members only.

The historical data trend for Getein Biotech's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Getein Biotech Construction In Progress Chart

Getein Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 80.86 86.37 205.76 225.08 272.63

Getein Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 248.36 256.70 271.10 272.63 276.84
SHSE:603387
77GF Score
Getein Biotech Inc SHSE:603387
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Getein Biotech Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ¥277 Mil mean?
Getein Biotech (SHSE:603387) has a Construction In Progress of ¥277 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Getein Biotech and its competitors.
Is Getein Biotech's Construction In Progress too high?
Getein Biotech's current Construction In Progress is ¥277 Mil. Overall, Getein Biotech has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getein Biotech's Construction In Progress compare to ABT and SYK?
Getein Biotech's Construction In Progress of ¥277 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Medical Devices & Instruments company?
A good Construction In Progress depends on the Medical Devices & Instruments industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Getein Biotech and its competitors. Getein Biotech's current Construction In Progress is ¥277 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Getein Biotech (SHSE:603387) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥7.56, compared to a current price of ¥8.90 — trading 17.7% above its estimated fair value. The current Construction In Progress is ¥277 Mil. Getein Biotech's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Getein Biotech (SHSE:603387), the current Construction In Progress is ¥277 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Getein Biotech (SHSE:603387) Overvalued in 2026?

Based on GuruFocus' analysis, Getein Biotech stock appears to be overvalued. The current stock price of ¥8.90 is trading 17.7% above its estimated GF Value™ of ¥7.56. GuruFocus considers Getein Biotech to be Modestly Overvalued.

Key valuation signals for SHSE:603387:

  • Construction In Progress: ¥277 Mil
  • GF Value™: ¥7.56 vs. price of ¥8.90 (17.7% above fair value)
  • GF Score™: 77/100 with 2 warning signs

No single metric tells the full story. See the SHSE:603387 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Getein Biotech Business Description

Address No. 9 Bofu Road, Luhe District, Nanjing, CHN, 211505
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
77GF Score

Get the complete analysis for SHSE:603387

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.90
Price
¥7.56
GF Value